Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / EDRN Longitudinal Serum Biorepository

EDRN Longitudinal Serum Biorepository

122
Lynch, HenryCreighton University
Lynch, HenryCreighton University

No involved investigator sites defined.

UNKNOWN
Breast and Gynecologic Cancers Research

Four percent of EDRN Registry mutation carriers developed cancer within a year after beginning follow-up in this registry; within 2 years, 10% had developed cancer. Within 2 years, 17% had developed either a cancer or a pre-malignant lesion (e.g. adenoma). Our goal is to recruit 265 mutation carriers from the EDRN High Risk Registry and Hereditary Cancer Center for the Longitudinal Serum Biorepository (LSB). Based on the cancer rates observed to date in the EDRN Registry, four years of follow-up in a group of this size would be expected to yield 53 invasive and in situ cancers and 37 benign premalignant lesions. All subjects in the serum biorepository (1)have signed consent (2) are counseled carriers (APC, BRCA1, BRCA2, CDH1, CDKN2A, MLH1, MSH2, MSH6) and (3) are enrolled in family studies through CU's Department of Preventive Medicine and/or are enrolled in the EDRN High Risk Registry. Post specimen medical history is collected annually. Serum and plasma are aliquoted for respository storage and stored in labeled cryovials in an ultra low temperature (-86C) freezer. Specimens in the LSB are available for use in EDRN biomarker development and validation studies.

To develop a longitudinal serum biorepository with annual serial samples collected from mutation carriers within the Hereditary Cancer Institute and High Risk Registry for retrospective evaluation of promising biomarkers.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place October 15–16, 2015 in Bethesda, Maryland.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to http://grants.nih.gov /grants/guide/ pa-files/ PAR-15-289.html.

Announcement 04/08/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held October 15-16, 2015 on the NCI campus. More information will be available later this summer.